News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,488 Results
Type
Article (39047)
Company Profile (279)
Press Release (646162)
Section
Business (203862)
Career Advice (1991)
Deals (35362)
Drug Delivery (85)
Drug Development (80799)
Employer Resources (169)
FDA (16086)
Job Trends (14803)
News (344538)
Policy (32435)
Tag
Academia (2530)
Alliances (49078)
Alzheimer's disease (1228)
Approvals (16018)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11533)
Biotechnology (200)
Breast cancer (119)
Cancer (1077)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (231)
Clinical research (64232)
Collaboration (384)
Compensation (197)
COVID-19 (2530)
C-suite (94)
Data (1119)
Diabetes (152)
Diagnostics (6138)
Earnings (84815)
Employer resources (147)
Events (109446)
Executive appointments (307)
FDA (16616)
Funding (346)
Gene therapy (176)
GLP-1 (574)
Government (4323)
Healthcare (18668)
Infectious disease (2614)
Inflammatory bowel disease (106)
Interviews (309)
IPO (16295)
Job creations (3624)
Job search strategy (1418)
Layoffs (413)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19138)
Metabolic disorders (398)
Neuroscience (1503)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1474)
Obesity (228)
Opinion (179)
Patents (101)
People (56260)
Phase I (19947)
Phase II (28293)
Phase III (21094)
Pipeline (454)
Postmarket research (2553)
Preclinical (8487)
Radiopharmaceuticals (235)
Rare diseases (217)
Real estate (5890)
Regulatory (21516)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1297)
Startups (3561)
United States (13376)
Vaccines (548)
Weight loss (166)
Date
Today (132)
Last 7 days (786)
Last 30 days (3729)
Last 365 days (35581)
2024 (32587)
2023 (40074)
2022 (51176)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37115)
Australia (6057)
California (3307)
Canada (1282)
China (247)
Colorado (143)
Connecticut (150)
Europe (79489)
Florida (455)
Georgia (116)
Illinois (338)
Indiana (195)
Kansas (96)
Maryland (573)
Massachusetts (2587)
Michigan (157)
Minnesota (271)
New Jersey (947)
New York (949)
North Carolina (696)
Northern California (1474)
Ohio (138)
Pennsylvania (839)
South America (1091)
Southern California (1297)
Texas (458)
Utah (90)
Washington State (357)
685,488 Results for "athersys inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
Athersys, Inc., announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock at a purchase price of $0.32 per share.
August 17, 2023
·
4 min read
Business
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
Athersys, Inc. announced financial results for the three and nine months ended September 30, 2023 and provided a business update.
November 16, 2023
·
11 min read
Business
Athersys Director Jane Wasman Appointed Board Chair
Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders.
October 2, 2023
·
8 min read
BioMidwest
Athersys Licenses its Animal Health Assets to Ardent Animal Health
Athersys, Inc., a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, and Multipotent Adult Progenitor Cell technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health.
October 3, 2023
·
10 min read
Business
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced the appointment of Neema Mayhugh, PhD to its Board of Directors.
August 11, 2023
·
10 min read
BioMidwest
Athersys Restructures Debt with Supplier
Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier.
May 23, 2023
·
8 min read
BioMidwest
Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
Athersys, Inc. announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation’s Medical Research Council to explore the potential use of Athersys’ MultiStem cellular therapy during machine perfusion prior to kidney transplantation.
September 6, 2023
·
9 min read
Business
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update.
August 16, 2023
·
11 min read
BioMidwest
Athersys to Host Business Update Conference Call on August 9th
Athersys, Inc., a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, announced it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time.
July 31, 2023
·
3 min read
BioMidwest
Athersys to Participate in Three Upcoming Conferences
Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announced its participation in three upcoming conferences during the month of May.
May 8, 2023
·
9 min read
1 of 68,549
Next